Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Standard BioTools ( (LAB) ) has issued an update.
On August 28, 2025, Standard BioTools Inc. announced a strategic restructuring plan to consolidate its R&D capabilities from South San Francisco to its Singapore facility, aligning with its manufacturing operations. This move, aimed at enhancing operational efficiency and reducing costs, involves a reduction-in-force affecting U.S. employees and is expected to incur expenses of approximately $3.6 million, with potential for additional costs due to unforeseen events.
The most recent analyst rating on (LAB) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Standard BioTools stock, see the LAB Stock Forecast page.
Spark’s Take on LAB Stock
According to Spark, TipRanks’ AI Analyst, LAB is a Neutral.
The overall stock score reflects significant financial challenges and valuation concerns, partially offset by positive corporate events. The strategic sale to Illumina is a key positive factor, but financial performance remains a critical risk.
To see Spark’s full report on LAB stock, click here.
More about Standard BioTools
Standard BioTools Inc. operates in the biotechnology industry, focusing on the development and manufacturing of advanced tools for biological research and analysis.
Average Trading Volume: 1,760,797
Technical Sentiment Signal: Sell
Current Market Cap: $481.3M
See more data about LAB stock on TipRanks’ Stock Analysis page.